Advanced imaging to see how immunosuppression affects lung fibrosis activity
Official title: Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Lung Fibrosis in Participants With Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Disease
Run by Massachusetts General Hospital · NCT07572383 · Data updated 2026-11-12
This trial will test whether immunosuppression changes PET and MRI measurements of active collagen deposition and tissue injury in people with non‑IPF interstitial lung disease who are starting treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | Massachusetts General Hospital Academic / other |
| Drugs / interventions | radiation, prednisone |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | May 14, 2026 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2028 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT07572383 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 with non‑IPF ILD (chronic hypersensitivity pneumonitis, connective tissue‑related ILD, or undifferentiated ILD) who are starting mycophenolate and/or prednisone, have CT evidence of fibrosis, and have FVC ≥45% and DLCO ≥25% predicted are the intended candidates.
✕Probably not a fit
People with idiopathic pulmonary fibrosis, prior or current use of antifibrotic drugs, emphysema exceeding fibrosis, severe lung function impairment (FVC <45% or DLCO <25%), pregnancy, or contraindications to MRI are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Fifteen adults with non‑IPF interstitial lung disease who are starting clinically indicated immunosuppression will undergo targeted molecular PET ([68Ga]CBP8) and dynamic contrast‑enhanced MRI (DCE‑MRI) before treatment and 12 weeks after initiation. The PET tracer binds to actively deposited collagen while DCE‑MRI provides measures of tissue injury and perfusion, allowing paired comparison of imaging biomarkers pre‑ and post‑therapy. Participants will be treated with mycophenolate (or its salts) and/or prednisone as prescribed by their clinicians, with imaging timed around treatment start. The study is single‑center and conducted at Massachusetts General Hospital with NHLBI collaboration.
Why it matters
Potential benefit: If successful, this approach could give clinicians a noninvasive way to see whether immunosuppression is reducing active collagen deposition and tissue injury, helping tailor treatment decisions.
How similar studies have gone: Targeted collagen PET tracers and DCE‑MRI have encouraging preclinical and early human feasibility data, but using them together to track immunosuppression response in non‑IPF ILD is relatively novel and not yet widely validated.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18-80 with a diagnosis of chronic hypersensitivity pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD. 2. Starting immunosuppression treatment with mycophenolate mofetil, mycophenolate sodium, and / or prednisone for clinically indicated non-IPF ILD treatment. 3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1. 4. Forced vital capacity (FVC) of \>/= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) \>/= 25% predicted on PFTs performed at Visit 1. Exclusion criteria: 1. Current or prior exposure to FDA approved anti-fibrotic therapy. 2. Extent of emphysema greater than extent of fibrosis. 3. Pregnancy or plans to become pregnant at baseline or during follow-up. 4. Contraindications to MRI. 5. Contraindications to receiving gadolinium-based contrast agents. 6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year. 7. Estimated glomerular filtration rate (eGFR) \< 30 mL/min (only for individuals with a history of chronic kidney disease). 8. Clinically significant pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy. 9. Respiratory infection within the prior 6 weeks. 10. Smoking of any kind within the prior 6 months.
Where it's running
-
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Sydney Montesi, MD — Massachusetts General Hospital
- Study coordinator: Sydney Montesi, MD
- Email: sbmontesi@mgb.org
- Phone: 617 724 4030
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CT
This study tests how well the AccuPulmo CT Portal can identify pulmonary fibrosis on existing chest CT scans from adults at Taichung Veterans General Hospital.
-
Understanding genetic and environmental factors in pulmonary fibrosis
This study looks at how genes and environmental factors affect pulmonary fibrosis to help understand the disease better for people who have it.
-
Identifying biomarkers for progressive pulmonary fibrosis in lung disease patients
This study is trying to find early signs that can help predict if adults with certain lung diseases will develop progressive pulmonary fibrosis over the next five years.
-
Using breath analysis to identify multiple lung diseases
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
-
Biobank for interstitial lung diseases
This study is setting up a collection of health information and samples from patients with interstitial lung diseases to help researchers learn more about the condition and find better treatments.
-
Registry for individuals affected by pulmonary fibrosis
This study invites people with pulmonary fibrosis, along with their caregivers and family members, to share their experiences through online surveys to help researchers understand the condition better and possibly reach out for future studies.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.